Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation afterOxford‐AstraZenecavaccine: Case report and brief literature review

Abstract

Pityriasis rosea (PR) has been manifested in patients suffering from COVID‐19 as well as after vaccine protocols against SARS‐CoV‐2. It has a possible association with the HHV‐6B virus ( roseola infantum ) and can be controlled by antivirals such as acyclovir as well as by the amino acid l ‐Lysine that showed a positive result in reducing the number of lesions and healing time. The aim of this study was to report a case of PR after a second dose of Oxford‐AstraZeneca, the adopted therapy and a brief literature review. A 53‐year‐old woman, phototype II, presented an erythematous lesion in the posterior right thigh 15 days after the second dose of Oxford‐AstraZeneca vaccine. Eight days after the initial injury, new injuries appeared in the calf, buttocks and thighs. The diagnosis was PR with a 5‐week eruption cycle. The treatment consisted of the use of l ‐Lysine, 3 grams loading dose and 500 mg for 30 days and moisturizing/healing lotion, starting 14 days after the herald patch. After the 5th week of the disease cycle, there were no new eruptions and the repair cycle continued for up to 8 weeks leaving some residual skin spots. It is concluded that the patient may be a carrier a latent virus, HHV‐6, and the vaccine administration with immune system stimulation, would have activated the possible virus causing PR. l ‐Lysine helped to control the manifestation by limiting the number of lesions and their location, which were restricted to the legs, thighs and buttocks.

Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature

“…Cutaneous adverse reactions like hyperhidrosis, pruritis, urticaria, angioedema, post‐vaccination herpes zoster, pityriasis rosea, pityriasis rubra pilaris, erythema multiforme, erythema nodosum, generalized bullous‐fixed drug eruption, toxic epidermal necrolysis, and sweet syndrome have been reported following ChAdOx1 nCoV‐19 vaccine. 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 …”

Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

“…Finalmente, y aunque no es el enfoque particular de este artículo, vale la pena mencionar que cada vez hay mayor evidencia de que las manifestaciones dermatológicas también se asocian a las vacunas contra el SARS-CoV-2 [41][42][43][44]. En el estudio de McMahon y colaboradores, describen hasta 13 patrones dermatológicos asociados con las vacunas, entre ellos casos de PR, la gran mayoría causados por las vacunas Moderna y Pfizer, las más ampliamente utilizadas [45].…”

Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature

“…No reactive dermatoses have been reported for other vaccines until April 2021, where, at that time, more than one billion doses of COVID-19 vaccine have been administered all over the world [8]. Lately, limited cases of reactive dermatoses following Oxford-AstraZeneca vaccine administration, such as erythema nodosum and pityriasis rosea-like eruption, were reported [9][10][11]. Nevertheless, there were no reported cases of lichen planus-like eruption.…”